NASDAQ:OPTN OptiNose (OPTN) Stock Price, News & Analysis $0.41 +0.02 (+5.30%) (As of 05:45 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends About OptiNose Stock (NASDAQ:OPTN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get OptiNose alerts:Sign Up Key Stats Today's Range$0.37▼$0.4550-Day Range$0.34▼$0.7952-Week Range$0.32▼$2.10Volume696,740 shsAverage Volume780,930 shsMarket Capitalization$62.31 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingBuy Company OverviewOptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.Read More… OptiNose Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks86th Percentile Overall ScoreOPTN MarketRank™: OptiNose scored higher than 86% of companies evaluated by MarketBeat, and ranked 150th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingOptiNose has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOptiNose has only been the subject of 2 research reports in the past 90 days.Read more about OptiNose's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for OptiNose are expected to grow in the coming year, from ($0.20) to ($0.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OptiNose is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OptiNose is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.11% of the outstanding shares of OptiNose have been sold short.Short Interest Ratio / Days to CoverOptiNose has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in OptiNose has recently decreased by 56.66%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOptiNose does not currently pay a dividend.Dividend GrowthOptiNose does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-2.10 Percentage of Shares Shorted2.11% of the outstanding shares of OptiNose have been sold short.Short Interest Ratio / Days to CoverOptiNose has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in OptiNose has recently decreased by 56.66%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.40 News SentimentOptiNose has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for OptiNose this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for OPTN on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added OptiNose to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, OptiNose insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.30% of the stock of OptiNose is held by insiders.Percentage Held by Institutions85.60% of the stock of OptiNose is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OptiNose's insider trading history. Receive OPTN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptiNose and its competitors with MarketBeat's FREE daily newsletter. Email Address OPTN Stock News HeadlinesOptinose, Inc.: Optinose Announces 1-for-15 Reverse Stock SplitDecember 28 at 1:12 AM | finanznachrichten.deOptiNose Shares to Reverse Split on Tuesday, December 31st (NASDAQ:OPTN)December 27 at 2:41 AM | americanbankingnews.comKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware of… yet have the potential to deliver colossal returns over the next four years. I’m not talking about Tesla, Palantir, or anything else you’ve heard parroted by the mainstream financial press. No. These are Trump’s Secret Stocks. December 30, 2024 | Porter & Company (Ad)Optinose Sets 1-for-15 Reverse Stock SplitDecember 26, 2024 | markets.businessinsider.comOptinose Announces 1-for-15 Reverse Stock SplitDecember 26, 2024 | globenewswire.comOptinose to Present at Piper Sandler Healthcare ConferenceDecember 4, 2024 | msn.comOptinose to Present at the Piper Sandler 36th Annual Healthcare ConferenceDecember 2, 2024 | globenewswire.comFormer Optinose CEO Peter Miller comes out of retirement to launch new startupDecember 2, 2024 | bizjournals.comSee More Headlines OPTN Stock Analysis - Frequently Asked Questions How have OPTN shares performed this year? OptiNose's stock was trading at $1.29 at the beginning of the year. Since then, OPTN shares have decreased by 68.0% and is now trading at $0.4131. View the best growth stocks for 2024 here. How were OptiNose's earnings last quarter? OptiNose, Inc. (NASDAQ:OPTN) announced its earnings results on Thursday, March, 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01. The company had revenue of $19.87 million for the quarter, compared to analysts' expectations of $19.90 million. When did OptiNose's stock split? Shares of OptiNose reverse split on the morning of Tuesday, December 31st 2024. The 1-15 reverse split was announced on Thursday, December 26th 2024. The number of shares owned by shareholders will be adjusted after the market closes on Monday, December 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did OptiNose IPO? OptiNose (OPTN) raised $101 million in an initial public offering (IPO) on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO. How do I buy shares of OptiNose? Shares of OPTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of OptiNose own? Based on aggregate information from My MarketBeat watchlists, some other companies that OptiNose investors own include NVIDIA (NVDA), CymaBay Therapeutics (CBAY), General Electric (GE), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET) and Adobe (ADBE). Company Calendar Last Earnings3/07/2024Today12/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OPTN CUSIPN/A CIK1494650 Webwww.optinose.com Phone(267) 364-3500FaxN/AEmployees190Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$5.00 Low Stock Price Target$1.00 Potential Upside/Downside+626.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,480,000.00 Net Margins-41.16% Pretax Margin-41.16% Return on EquityN/A Return on Assets-27.42% Debt Debt-to-Equity RatioN/A Current Ratio0.79 Quick Ratio0.72 Sales & Book Value Annual Sales$75.67 million Price / Sales0.82 Cash FlowN/A Price / Cash FlowN/A Book Value($0.77) per share Price / Book-0.54Miscellaneous Outstanding Shares150,829,000Free Float147,360,000Market Cap$62.31 million OptionableNot Optionable Beta-0.17 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (NASDAQ:OPTN) was last updated on 12/30/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored>>>RE: Buy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptiNose, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptiNose With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
